CLYM Climb Bio, Inc.
Price Chart
Executive Summary
Climb Bio filed a prospectus supplement for an at-the-market (ATM) offering of up to $100 million in common stock through Jefferies. The proceeds will be used for general corporate purposes, including R&D and working capital. This ATM adds potential dilution of ~9.2 million shares (16% of current float) on top of recent capital raises, creating near-term overhang.
Actionable Insight
The ATM overhang may pressure the stock as the company can sell shares at market prices. Monitor daily volume and any sales announcements. The company now has significant cash reserves after the private placement and this ATM, potentially reducing near-term funding risk but increasing dilution.
Key Facts
- ATM offering of up to $100 million in common stock
- Jefferies LLC acting as sales agent with up to 3.0% commission
- Proceeds for general corporate purposes including R&D and working capital
- Potential dilution of approximately 9,165,902 shares at $10.91 per share
- No minimum offering amount; sales at market prices over time
- Follows April 2026 private placement that raised ~$103.4 million
Financial Impact
Up to $100 million in gross proceeds, net proceeds after commissions and expenses (estimated $400k) will vary
Risk Factors
- Immediate dilution of ~16% if the full $100 million is sold at current prices
- Continuous downward pressure on stock price due to potential share sales
- Uncertain use of proceeds and management discretion over capital allocation
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-269510 |
| Document: 0001193125-26-269510-index-headers.html | 0001193125-26-269510 |
| Document: 0001193125-26-269510-index.html | 0001193125-26-269510 |
| Document: 0001193125-26-269510.txt | 0001193125-26-269510 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
8-K
| $11.44 awaiting T+5 | awaiting T+5 | — | $11.44 (+0.00%) |
|
Jun 12, 2026
2d ago
|
424B5
| $11.44 awaiting T+5 | awaiting T+5 | — | $11.44 (+0.00%) |
|
Jun 10, 2026
5d ago
|
EFFECT
| $11.14 awaiting T+5 | awaiting T+5 | — | $11.44 (+2.69%) |
|
Jun 5, 2026
9d ago
|
8-K
| $10.77 awaiting T+5 | awaiting T+5 | — | $11.44 (+6.22%) |
|
May 29, 2026
16d ago
|
S-3
| $11.80 $10.55 | ▼ −10.59% | ▼ −7.84% | $11.44 (−3.05%) |
|
May 7, 2026
5w ago
|
8-K
| $11.91 $11.41 | ▼ −4.20% | ▼ −5.70% | $11.44 (−3.95%) |
|
May 5, 2026
5w ago
|
8-K
| $11.45 $11.17 | ▼ −2.45% | ▼ −4.43% | $11.44 (−0.09%) |
|
Apr 28, 2026
6w ago
|
8-K
| $9.26 $9.69 | ▼ −4.64% | ▼ −2.95% | $11.44 (−23.54%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $9.50 $9.69 | ▲ +2.00% | ▲ +1.60% | $11.44 (+20.42%) |
|
Apr 3, 2026
10w ago
|
8-K
| $6.74 $8.63 | ▲ +28.04% | ▲ +23.91% | $11.44 (+69.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access